Through a retrospective study of 67 patients with B-ALL in our center, Tocilizumab was recommended for patients whose clinical symptoms had meet the standard of ASTCT grade 2 and whose concentration of IL-6 had increased by more than four times (Figure 5). The gene discussed is IL6; the disease is acute lymphoblastic leukemia.